Cargando…
Engineering therapeutic antibodies targeting G-protein–coupled receptors
G-protein–coupled receptors (GPCRs) are one of the most attractive therapeutic target classes because of their critical roles in intracellular signaling and their clinical relevance to a variety of diseases, including cancer, infection and inflammation. However, high conformational variability, the...
Autores principales: | Jo, Migyeong, Jung, Sang Taek |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4892866/ https://www.ncbi.nlm.nih.gov/pubmed/26846450 http://dx.doi.org/10.1038/emm.2015.105 |
Ejemplares similares
-
Recent Achievements and Challenges in Prolonging the Serum Half-Lives of Therapeutic IgG Antibodies Through Fc Engineering
por: Ko, Sanghwan, et al.
Publicado: (2021) -
Mini-review: antibody therapeutics targeting G protein-coupled receptors and ion channels
por: Hutchings, Catherine J
Publicado: (2020) -
Construction of an immunotoxin via site-specific conjugation of anti-Her2 IgG and engineered Pseudomonas exotoxin A
por: Lee, Byeong Sung, et al.
Publicado: (2019) -
G protein-coupled receptors as new therapeutic targets for type 2 diabetes
por: Reimann, Frank, et al.
Publicado: (2015) -
Hemorphins Targeting G Protein-Coupled Receptors
por: Ayoub, Mohammed Akli, et al.
Publicado: (2021)